Sunshine Biopharma, Inc.
SBFM
$2.18
$0.041.87%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -9.13% | -10.61% | 11.64% | 1.15% | 18.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.13% | -10.61% | 11.64% | 1.15% | 18.04% |
| Cost of Revenue | -4.26% | -14.67% | 13.91% | -13.81% | 18.98% |
| Gross Profit | -20.12% | -2.08% | 7.23% | 45.27% | 15.98% |
| SG&A Expenses | -8.19% | -8.72% | -12.20% | 34.85% | 8.07% |
| Depreciation & Amortization | 18.67% | 51.22% | 48.30% | 42.44% | 52.11% |
| Other Operating Expenses | 17.70% | 16.27% | 112.21% | -22.70% | 45.19% |
| Total Operating Expenses | -6.99% | -12.01% | 4.27% | -1.59% | 14.68% |
| Operating Income | -7.70% | 18.62% | 51.92% | 21.72% | 4.06% |
| Income Before Tax | -1.97% | 24.24% | -3.94% | -136.28% | 3.29% |
| Income Tax Expenses | -- | 417.33% | -163.85% | 39.13% | -279.46% |
| Earnings from Continuing Operations | -5.43% | 0.80% | 26.21% | -258.24% | 8.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.43% | 0.80% | 26.21% | -258.24% | 8.10% |
| EBIT | -7.70% | 18.62% | 51.92% | 21.72% | 4.06% |
| EBITDA | -7.12% | 20.92% | 58.16% | 24.40% | 5.89% |
| EPS Basic | 41.90% | 56.03% | 79.47% | 80.32% | 80.18% |
| Normalized Basic EPS | 43.82% | 68.97% | 87.08% | -- | 79.14% |
| EPS Diluted | 41.90% | 56.03% | 79.47% | 80.32% | 80.18% |
| Normalized Diluted EPS | 43.82% | 68.97% | 87.08% | -- | 79.14% |
| Average Basic Shares Outstanding | 81.50% | 125.59% | 259.43% | -- | -61.68% |
| Average Diluted Shares Outstanding | 81.50% | 125.59% | 259.43% | 601.12% | -61.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |